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Poster Session I 37myeloma (MM). While most of the pts relapse after ASCT with
a median time to progression (TTP) of 2 years, there is a significant
heterogeneity in the duration of response. It has been hypothesized
that the effect of high dose alkylator therapy used for conditioning
may have a dual effect on the MMcells as well as marrow microen-
vironment. It is also known that hematopoiesis, especially thrombo-
poiesis, depends to some extent on signals form the marrow
microenvironment. We examined if there was any relationship be-
tween delayed platelet engraftment and outcome after ASCT.
Methods:We examined the outcomes in a group of pts undergoing
ASCT for MM at our institution to compare the response duration
to platelet engraftment kinetics. We studied 687 pts undergoing
ASCTwith melphalan conditioning followed by PB stem cells.Re-
sults: Among the 687 pts undergoing ASCT, 200 (29%) achieved
a platelet count of 50,000 by day 21 (early group) and the rest
achieved this level after 21 days or never engrafted (late group).
The TTP) among the late group was 24.8 mos (95% CI; 19.6, 30)
vs. 16.8 mos (95% CI; 15.1, 18.6) for the late group (p\ 0.001).
Pts in the late engraftment group weremore likely to achieve a com-
plete response compared to the early group; 39% vs. 30%, p5 0.02.
In a multivariate analysis examining factors predicting for longer
TTP after ASCT, delayed platelet engraftment was independent
of ASCT within 12 months of diagnosis, CR with ASCT, absence
of cytogenetic abnormalities, B2M\3.5 mg/L and a plasma cell la-
beling index\1% at the time of ASCT.Conclusions: In this study,
we have demonstrated for the first time a relationship between de-
layed platelet engraftment after ASCT and the duration of response
following ASCT. This intriguing finding raises several hypotheses.
It is possible that the delayed platelet engraftment is a marker of
marrow microenvironment dysfunction secondary to high dose
therapy, given the role of marrow microenvironment on thrombo-
poiesis. It is possible that this is a surrogatemarker for the biological
effectiveness of the melphalan dose, which can affect the other cells
in the marrow microenvironment as well. It is likely a reflection of
the marrow microenvironment dependence on the myeloma cells
for its survival. These findings should be confirmed in other larger
patient groups.95
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Significance and Background: High-dose therapy and autolo-
gous stem cell transplant (HDT/SCT) is complicated by an ex-
pected period of pancytopenia, through which the patient must be
supported.With the introduction of granulocyte colony stimulating
factors in the early 1990s, this period was shortened. Still, pro-
longed neutropenia puts the patient at risk of infection which may
have serious consequences and may be fatal. Pegfilgrastim, a pegy-
lated version of filgrastim, has been used as post-HDT/SCTgrowth
factor support in a small number of European centers, but its use in
the United States for this indication has not been widely adopted.
Purpose: To evaluate the use of Neulasta (pegfilgrastim) as
post-transplant colony stimulating factor support compared to
Neupogen (filgrastim) for adult autologous SCT patients. Inter-
ventions: Between February and September 2007, we treated 56
patients who were undergoing HDT/SCT as standard of care
with pegfilgrastim 6 mg subcutaneously once on day 1 1. Patient
and treatment characteristics are detailed in the table below. We
compared this sample to an historical control sample of 190 patients
in 2005 who were treated with filgrastim (flat weight-based dosing)
starting on either day1 5 or day 1 1 and continuing until engraft-
ment. Evaluation: Mean day to neutrophil engraftment . 500 K/
mcL for the pegfilgrastim sample was 9.6 days (median 9 days),
compared to the historical control sample (mean 10.49 days; median
10 days). AverageWholesale Price (AWP) is not dramatically differ-
ent ($3,557 for Neulasta  1; $3090 for Neupogen 480 mcg  7
daily doses). One patient had a slow ANC engraftment (day 1
22). No patient had a delayed hospital discharge due to red bloodcell or platelet transfusion requirements. One patient had a pro-
tracted hospital course due to infectious complications; two patients
required transfer to the intensive care unit, one for sepsis, one for
infection and myocardial infarction. There were no observations
of clinically significant post-engraftment fevers or engraftment syn-
drome. Treatment related mortality in this cohort was 0%.Discus-
sion: Neulasta is equally efficacious in neutrophil recovery as
Neupogen post autologous HDT/SCT. It has the advantage of re-
quiring only one injection for the patient and appears to potentiate
a reduction in overall hospital length of stay.Patient/Treatment CharacteristicsGender
Male 33
Female 23Median Age 55
Diagnosis
Diffuse Large B Cell
Lymphoma8Mantle Cell
Lymphoma8Peripheral T Cell
Lymphoma3Hodgkin Lymphoma 6
Multiple myeloma 27
AL Amyloidosis 4Conditioning
BEAM 18
CBV 4
MELPHALAN 31
TBI/CY/ETOP 396
INCIDENCE AND FACTORS INFLUENCING STEM CELL MOBILIZATION IN
PATIENTS WITH NON-HODGKIN’S LYMPHOMA (NHL) AND HODGKIN’S
DISEASE (HD)
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Background: Autologous transplantation from peripheral blood
stem cells is an important curative therapeutic option in patients
with chemosensitive Hodgkin’s (HD) and non-Hodgkin’s Lym-
phoma (NHL), but is not available for patients who fail to mobilize.
In this study we wished to estimate the incidence of mobilization
failure in lymphoma patients seen atM.D. AndersonCancer Center
and identify predictive factors. Methods: We retrospectively re-
viewed charts of all patients referred in the calendar years 2003
and 2004 with NHL and HD, in whom peripheral blood stem
cell collection was attempted. Mobilization failure was defined as
inability to collect 2  106 CD341 cells/Kg. Predictors of mobili-
zation failure were evaluated using logistic regression analysis in-
cluding type of mobilization chemotherapy, age, sex, number of
prior chemotherapies, bone marrow cellularity, platelet count,
white blood cell count, prior bone marrow involvement with malig-
nancy, and prior radiation. Results: During the study period, 206
patients, 130 males and 76 females with a median age of 48 years
(range 10–81 years) were deemed eligible for autologous transplant
and underwent stem cell mobilization. Sixty five patients had HD
and 141 patients had NHL. Mobilization regimens were as follows:
Ifosfamide and Etoposide 147, Cyclophosphamide 14, other che-
motherapeutic regimens 26, and G-CSF alone 19. Twenty-nine
of 206 (14%) patients failed to mobilize stem cells. The majority
of these cases (26/29) were NHL patients (odds ratio for NHL ver-
sus HD: 4.7; p5 0.01). On univariate analysis, use of G-CSF alone
as opposed to chemotherapy, platelet count\150K/ul, and bone
marrow cellularity\ 30% were the only significant predictors of
mobilization failure in NHL. In view of small number of patients
multivariate analysis was not possible. However, a low platelet
